Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

NCT01945710 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.

NCT NCT01945710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01945710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
Lead sponsor
Eisai Limited
Phase
Phase 1
Overall status
Completed
Start date
December 11, 2012
Completion date
May 17, 2016
Enrollment
62 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors